{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "http://www.interprotein.com/#organization",
      "name": "Interprotein Corporation",
      "url": "http://www.interprotein.com/",
      "description": "Interprotein Corporation Your browser does not support JavaScript! [Japanese Top] Top Company Corporate Profile Message from the CEO History Access Site Policy Business Overview Business Outline Business Strategy In-house projects Anti-COVID-19 drugs Tumor angiogenesis inhibitor IL-6 inhibitor Notch 1 inhibitor Tubulin polymerization inhibitor TIM-3 inhibitor NKG2A/HLA-E/CD94 inhibitor KIR/HLA-C inhibitor gp130 inhibitor RUNX1/CBFβ inhibitor Alliances with pharmaceutical company Platform Technologies INTENDD ® AI-guided INTENDD ® Helix-loop-helix peptide Presentation materials News & Topics Careers With twin platform technologies, Interprotein provides highly active modulators f"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/interprotein-corporation#asg",
      "name": "Interprotein Corporation ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/interprotein-corporation",
      "isPartOf": {
        "@id": "http://www.interprotein.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}